AUROBINDO PHARMA Share Price Up by 10%; BSE HEALTHCARE Index Up 1.4%
January 25, 2021 01:27 PM

AUROBINDO PHARMA share price has zoomed 10% and is presently trading at Rs 1,021.

Meanwhile, the BSE HEALTHCARE Index is at 21,676 (up 1.4%).

Among the top Gainers in the BSE HEALTHCARE Index today is AUROBINDO PHARMA (up 10.3%).

NATCO PHARMA (down 0.3%) and ERIS LIFESCIENCES (down 0.4%) are among the top losers today.

Over the last one year, AUROBINDO PHARMA has moved up from Rs 493 to Rs 1,021, registering a gain of Rs 528 (up 106.7%).

On the other hand, the BSE HEALTHCARE has moved up from 14,005 to 21,676, registering a gain of 7,671 points (up 54.5%) during the last 12 months.

The top buzzing stocks among the BSE HEALTHCARE Index stocks during this same period were LAURUS LABS (up 364.7%), GRANULES INDIA (up 146.2%) and STRIDES PHARMA SCIENCE (up 121.7%).

What About the Benchmark Indices?

The BSE Sensex is at 49,263 .

The top gainers among the BSE Sensex stocks today are AXIS BANK (up 3.3%), SUN PHARMA (up 2.8%) and TATA STEEL (up 1.8%). Other gainers include BAJAJ FINSERV (up 1.8%) and L&T (up 1.7%). The most traded stocks in the BSE Sensex are SBI and TATA STEEL.

In the meantime, NSE Nifty is at 14,491 (up 0.2%). The top gainers in the NSE Nifty include GRASIM (up 8.3%), CIPLA (up 5.7%) and UPL (up 4.1%). Other gainers include AXIS BANK (up 3.2%) and HERO MOTOCORP (up 2.8%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved up from 41,324 to 49,263, registering a gain of 7,939 points (up 18.29%).

AUROBINDO PHARMA Financial Update...

AUROBINDO PHARMA net profit stood at Rs 8 billion for the quarter ended June 2020, compared to a profit of Rs 7 billion a year ago. Net Sales rose 2.2% to Rs 59.2 billion during the period as against Rs 58.0 billion in April-June 2019.

For the year ended March 2019, AUROBINDO PHARMA reported 1.2% increase in net profit to Rs 24.5 billion compared to net profit of Rs 24.2 billion during FY18.

Revenue of the company grew 18.6% to Rs 196 billion during FY19.

The current Price to earnings ratio of AUROBINDO PHARMA, based on rolling 12 month earnings, stands at 19.9x.